Variant position: 164 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 465 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human LPLGFTFSFPVRHEDIDKGI LLNWTKGFKASGAEGNNVVGL
Mouse LPLGFTFSFPVRHEDIDKGI LLNWTKGFKASGAEGNNIVGL
Rat LPLGFTFSFPVRHEDLDKGI LLNWTKGFKASGAEGNNIVGL
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
1 – 465 Glucokinase
10 – 454 Hexokinase
67 – 203 Hexokinase small subdomain
177 – 177 E -> K. Small change in glucokinase activity.
161 – 164
Identification of glucokinase mutation in subjects with post-renal transplantation diabetes mellitus.
Nam J.H.; Lee H.C.; Kim Y.H.; Cha B.S.; Song Y.D.; Lim S.K.; Kim K.R.; Huh K.B.;
Diabetes Res. Clin. Pract. 50:169-176(2000)
Cited for: VARIANT MODY2 PRO-164;
Phenotypic severity of homozygous GCK mutations causing neonatal or childhood-onset diabetes is primarily mediated through effects on protein stability.
Raimondo A.; Chakera A.J.; Thomsen S.K.; Colclough K.; Barrett A.; De Franco E.; Chatelas A.; Demirbilek H.; Akcay T.; Alawneh H.; Flanagan S.E.; Van De Bunt M.; Hattersley A.T.; Gloyn A.L.; Ellard S.;
Hum. Mol. Genet. 23:6432-6440(2014)
Cited for: VARIANTS PNDM LYS-40; CYS-43; ASP-50; ARG-72; THR-151; PRO-164; ALA-168; ARG-169; ARG-261; THR-393; LEU-397; LEU-441 AND THR-449; CHARACTERIZATION OF VARIANTS PNDM LYS-40; CYS-43; ASP-50; ARG-72; ALA-168; ARG-261; THR-393; LEU-397; LEU-441 AND THR-449; VARIANTS MODY2 ASN-160 AND MET-226; CHARACTERIZATION OF VARIANT MODY2 ASN-160 AND MET-226; FUNCTION; CATALYTIC ACTIVITY;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.